Tags

Type your tag names separated by a space and hit enter

Clinical application of neutrophil gelatinase-associated lipocalin in the revised chronic kidney disease classification.
Int J Clin Exp Pathol. 2014; 7(10):7172-81.IJ

Abstract

BACKGROUND

A revised classification of chronic kidney disease (CKD) was proposed by the Kidney Disease: Improving Global Outcomes (KDIGO) in 2012. Neutrophil gelatinase-associated lipocalin (NGAL) was considered as one of the most promising biomarkers in clinical nephrology. The aim of this study was to examine the level of NGAL in patients with different impairment of GFR based on the new classification, and to evaluate whether NGAL in serum or urine was associated with different risk categories in CKD patients.

METHODS

A cross-sectional study was performed in 240 patients with CKD. NGAL, serum cystatin C, β₂-macroglobulin (β₂-MG), urine α₁-macroglobulin (α₁-MG) and albuminuria were tested in patients with various degrees of renal impairment.

RESULTS

Good correlation was found between the NGAL and the cystatin C, β₂-MG and the α₁-MG (r > 0.7). The level of sNGAL in CKD stage 3b was more than that in CKD stage 3a (P = 0.025). The concentration of the NGAL increased progressively with the increasing of risk categories (proposed by the revised CKD classification). The cutoff value of NGAL was calculated from stage 2 to stage 5. ROC analysis showed good AUC (sNGAL > 0.8, uNGAL > 0.7) and high specificity (sNGAL > 87%, uNGAL > 90%) on the cutoff value of NGAL.

CONCLUSION

The results confirm NGAL as a useful biomarker in clinical nephrology which is helpful to diagnosis and evaluate the categories for CKD proposed by the KDIGO.

Authors+Show Affiliations

Department of Clinical Laboratory, Chinese People's Liberation Army General Hospital Beijing 100853, China.Ningbo Women & Children's Hospital Ningbo 315031, China.Department of Clinical Laboratory, Chinese People's Liberation Army General Hospital Beijing 100853, China.Department of Clinical Laboratory, Chinese People's Liberation Army General Hospital Beijing 100853, China.Department of Clinical Laboratory, Chinese People's Liberation Army General Hospital Beijing 100853, China.School of Labroratory Medicine and Life Science, Wenzhou Medical College Whenzhou 325000, China.Department of Clinical Laboratory, Chinese People's Liberation Army General Hospital Beijing 100853, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25400814

Citation

Xiang, Daijun, et al. "Clinical Application of Neutrophil Gelatinase-associated Lipocalin in the Revised Chronic Kidney Disease Classification." International Journal of Clinical and Experimental Pathology, vol. 7, no. 10, 2014, pp. 7172-81.
Xiang D, Zhang H, Bai J, et al. Clinical application of neutrophil gelatinase-associated lipocalin in the revised chronic kidney disease classification. Int J Clin Exp Pathol. 2014;7(10):7172-81.
Xiang, D., Zhang, H., Bai, J., Ma, J., Li, M., Gao, J., & Wang, C. (2014). Clinical application of neutrophil gelatinase-associated lipocalin in the revised chronic kidney disease classification. International Journal of Clinical and Experimental Pathology, 7(10), 7172-81.
Xiang D, et al. Clinical Application of Neutrophil Gelatinase-associated Lipocalin in the Revised Chronic Kidney Disease Classification. Int J Clin Exp Pathol. 2014;7(10):7172-81. PubMed PMID: 25400814.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical application of neutrophil gelatinase-associated lipocalin in the revised chronic kidney disease classification. AU - Xiang,Daijun, AU - Zhang,Hongrui, AU - Bai,Jie, AU - Ma,Junlong, AU - Li,Mianyang, AU - Gao,Jimin, AU - Wang,Chengbin, Y1 - 2014/09/15/ PY - 2014/08/20/received PY - 2014/09/15/accepted PY - 2014/11/18/entrez PY - 2014/11/18/pubmed PY - 2015/7/7/medline KW - KDIGO KW - Neutrophil gelatinase-associated lipocalin KW - chronic kidney disease SP - 7172 EP - 81 JF - International journal of clinical and experimental pathology JO - Int J Clin Exp Pathol VL - 7 IS - 10 N2 - BACKGROUND: A revised classification of chronic kidney disease (CKD) was proposed by the Kidney Disease: Improving Global Outcomes (KDIGO) in 2012. Neutrophil gelatinase-associated lipocalin (NGAL) was considered as one of the most promising biomarkers in clinical nephrology. The aim of this study was to examine the level of NGAL in patients with different impairment of GFR based on the new classification, and to evaluate whether NGAL in serum or urine was associated with different risk categories in CKD patients. METHODS: A cross-sectional study was performed in 240 patients with CKD. NGAL, serum cystatin C, β₂-macroglobulin (β₂-MG), urine α₁-macroglobulin (α₁-MG) and albuminuria were tested in patients with various degrees of renal impairment. RESULTS: Good correlation was found between the NGAL and the cystatin C, β₂-MG and the α₁-MG (r > 0.7). The level of sNGAL in CKD stage 3b was more than that in CKD stage 3a (P = 0.025). The concentration of the NGAL increased progressively with the increasing of risk categories (proposed by the revised CKD classification). The cutoff value of NGAL was calculated from stage 2 to stage 5. ROC analysis showed good AUC (sNGAL > 0.8, uNGAL > 0.7) and high specificity (sNGAL > 87%, uNGAL > 90%) on the cutoff value of NGAL. CONCLUSION: The results confirm NGAL as a useful biomarker in clinical nephrology which is helpful to diagnosis and evaluate the categories for CKD proposed by the KDIGO. SN - 1936-2625 UR - https://www.unboundmedicine.com/medline/citation/25400814/Clinical_application_of_neutrophil_gelatinase_associated_lipocalin_in_the_revised_chronic_kidney_disease_classification_ DB - PRIME DP - Unbound Medicine ER -